Innate Pharma (IPHA) FDA catalyst dates

FreeBioList tracks 2 upcoming catalysts for Innate Pharma (IPHA, listed on Nasdaq). They cover 2 programmes: IPH4502 (Advanced solid tumours (Nectin-4 ADC)) and Monalizumab + durvalumab (Unresectable stage III NSCLC).

First on the list: the Phase 1 readout for IPH4502 (Advanced solid tumours (Nectin-4 ADC)), dated 18 Nov 2026. By stage, the upcoming rows are 1 Phase 1 readout and 1 Phase 3 readout.

Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 07 Oct 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4; How to read a Phase 3 topline readout.

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Innate Pharma IPHA · Nasdaq	IPH4502	Advanced solid tumours (Nectin-4 ADC)	18 Nov 2026 in 41d	Phase 1 readout	Verified	6-K exhibit 99.1 ↗	No
Notes — Filing states: "Initial Phase 1 dose-escalation data will be presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) on November 18, 2026." Source: 6-K exhibit 99.1, filed 17 Sep 2026 · verified 07 Oct 2026
Innate Pharma IPHA · Nasdaq	Monalizumab + durvalumab	Unresectable stage III NSCLC	H2 2026 company guidance	Phase 3 readout	Verified	6-K exhibit 99.1 ↗	No
Notes — Filing states: "PACIFIC-9 Phase 3 readout for monalizumab, led by AstraZeneca, expected in H2 2026"; the CEO adds "by year-end". Source: 6-K exhibit 99.1, filed 17 Sep 2026 · verified 07 Oct 2026

Companies working on related conditions

Aktis Oncology (AKTS)Urothelial and Nectin-4 expressing solid tumours (radiopharmaceutical); Metastatic castration-resistant prostate cancer (B7-H3 radiopharmaceutical)
Compass Therapeutics (CMPX)Biliary tract cancer (DLL4 x VEGF-A bispecific); TNBC, NSCLC and Hodgkin lymphoma post-checkpoint (PD-1 x PD-L1); Solid tumours (PD-1 x VEGF-A bispecific)
Eikon Therapeutics (EIKN)Non-squamous NSCLC (TLR7/8 agonist); Melanoma — first interim analysis; Advanced solid tumours (PARP1-selective); Advanced solid tumours (WRN helicase inhibitor
MacroGenics (MGNX)Advanced solid tumours (B7-H3 ADC); Advanced solid tumours (ADAM9 ADC); Clear cell gynaecologic cancer (PD-1 x CTLA-4)
Aprea Therapeutics (APRE)Advanced solid tumours (WEE1 inhibitor)
ArriVent BioPharma (AVBP)First-line EGFR exon 20 insertion NSCLC

Also due in Q4 2026

Enanta Pharmaceuticals (ENTA)Phase 1 readout for EDP-978, Q4 2026
Arvinas (ARVN)Phase 1 readout for ARV-102, Oct 2026
Xencor (XNCR)Phase 1 readout for XmAb819, Oct 2026
Kyverna Therapeutics (KYTX)Phase 1 readout for Miv-cel (mivotacel), Q4 2026
Neumora Therapeutics (NMRA)Phase 1 readout for NMRA-511, Q4 2026
MBX Biosciences (MBX)Phase 1 readout for MBX 4291, Q4 2026